Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Genalyte Inc. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 2 distinct examiners, though they remain centralized within 1 distinct art unit. This configuration suggests that while the technical focus is narrow, the company must navigate the individual examination styles of multiple USPTO officials simultaneously.
The busiest examiner for this portfolio is KIRWIN, STEFANIE JOHANNA, who is handling 1 busiest examiner pending action. The second of the 2 pending office actions is assigned to the other of the 2 distinct examiners. Because all active prosecution occurs within 1 distinct art unit, the overarching administrative guidelines and supervisory oversight remain consistent across both cases.
For the practitioner, managing 2 distinct examiners within the same art unit requires a balanced approach. While the technical standards of the Biotechnology & Pharmaceuticals division apply to both actions, the specific feedback from KIRWIN, STEFANIE JOHANNA may differ from the other examiner. This environment necessitates a strategy that accounts for individual examiner nuances while maintaining a cohesive technical narrative within the single art unit.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIRWIN, STEFANIE JOHANNA | 1 | 15.9% | +31.6% |
| MARCSISIN, ELLEN JEAN | 1 | 34.5% | +49.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17051278 | METHODS AND COMPOSITIONS FOR POINT OF CARE MEASUREMENT OF THE BIOAVAILABILITY OF THERAPEUTIC BIOLOGICS | MARCSISIN, ELLEN JEAN | 285d overdue |
| 17220888 | RAPID MULTIPLEXED SEROLOGICAL TEST | KIRWIN, STEFANIE JOHANNA | 7d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17051278 | METHODS AND COMPOSITIONS FOR POINT OF CARE MEASUREMENT OF THE BIOAVAILABILITY OF THERAPEUTIC BIOLOGICS | MARCSISIN, ELLEN JEAN | 285d overdue |
| 17220888 | RAPID MULTIPLEXED SEROLOGICAL TEST | KIRWIN, STEFANIE JOHANNA | 7d |
| Art Unit | Apps |
|---|---|
| 1677 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17220888 | RAPID MULTIPLEXED SEROLOGICAL TEST | KIRWIN, STEFANIE JOHANNA | 1677 | §102§103 | Final Rejection | 7d | Pending | Apr 01, 2021 |
| 17051278 | METHODS AND COMPOSITIONS FOR POINT OF CARE MEASUREMENT OF THE BIOAVAILABILITY OF THERAPEUTIC BIOLOGICS | MARCSISIN, ELLEN JEAN | 1677 | §103§112Other | Final Rejection | 285d overdue | Pending | Oct 28, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial